Proposed mechanisms by which CHM use might decrease the risk of developing depression include the inhibition of the monoamine oxidase activity and oxidative stress, upregulation of neurotrophins, and modulation of hypothalamic-pituitary-adrenal axis function (Dowlati et al., 2010; Wang Y. et al., 2019). This evidence concerns the gene BDNF and depressive symptom measurement.